129 related articles for article (PubMed ID: 15535401)
1. Clinical outcome to interferon therapy in chronic hepatitis C: insights from mechanistic studies.
Beard MR
Antivir Ther; 2004 Oct; 9(5):637-9. PubMed ID: 15535401
[No Abstract] [Full Text] [Related]
2. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
3. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes.
Meier V; Mihm S; Ramadori G
J Med Virol; 2008 Nov; 80(11):1912-8. PubMed ID: 18814253
[TBL] [Abstract][Full Text] [Related]
4. CD81 down-regulation on B cells is associated with the response to interferon-alpha-based treatment for chronic hepatitis C virus infection.
Chang LL; Cheng PN; Chen JS; Young KC
Antiviral Res; 2007 Jul; 75(1):43-51. PubMed ID: 17194487
[TBL] [Abstract][Full Text] [Related]
5. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy.
Hamamoto S; Uchida Y; Wada T; Moritani M; Sato S; Hamamoto N; Ishihara S; Watanabe M; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):204-8. PubMed ID: 15683422
[TBL] [Abstract][Full Text] [Related]
6. Correlation between translation efficiency and outcome of combination therapy in chronic hepatitis C genotype 3.
Yasmeen A; Hamid S; Granath FN; Lindström H; Elliott RM; Siddiqui AA; Persson MA
J Viral Hepat; 2006 Feb; 13(2):87-95. PubMed ID: 16436126
[TBL] [Abstract][Full Text] [Related]
7. Mutagenic effects of ribavirin in vivo.
Perelson AS; Ribeiro RM
J Hepatol; 2005 Oct; 43(4):553-5. PubMed ID: 16099528
[No Abstract] [Full Text] [Related]
8. Hepatocellular carcinoma and interferon therapy in HCV compensated cirrhosis: evaluation in relation to virological response.
Testino G; Icardi G
Hepatogastroenterology; 2005; 52(63):4 p preceding table of contents. PubMed ID: 15966175
[No Abstract] [Full Text] [Related]
9. [Disappearance of serum autoantibodies during treatment with interferon alpha in a patient with chronic hepatitis C].
Khemissa F; Bauget P; Michel H; Larrey D
Gastroenterol Clin Biol; 1997; 21(12):998-9. PubMed ID: 9587568
[No Abstract] [Full Text] [Related]
10. Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C.
Xu DZ; Xie Y; Li ZQ
Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):550-3. PubMed ID: 16286260
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hepatitis C--update 2005].
Forestier N; Zeuzem S
Dtsch Med Wochenschr; 2005 Dec; 130 Suppl 5():S215-6. PubMed ID: 16435713
[No Abstract] [Full Text] [Related]
12. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C.
Negro F; Clément S
J Viral Hepat; 2009 Oct; 16(10):681-8. PubMed ID: 19732324
[TBL] [Abstract][Full Text] [Related]
13. [Chronic hepatitis C infection--mechanisms of virus "immune escape"].
Nitkiewicz J
Przegl Epidemiol; 2004; 58(3):423-33. PubMed ID: 15730006
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of chronic viral hepatitis].
Pedersen C; Pedersen CR
Ugeskr Laeger; 2008 Jun; 170(24):2137-40. PubMed ID: 18565297
[TBL] [Abstract][Full Text] [Related]
15. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.
Tran HA; Malcolm Reeves GE; Gibson R; Attia JR
J Gastroenterol Hepatol; 2009 Jul; 24(7):1163-8. PubMed ID: 19682190
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin.
Milazzo L; Biasin M; Gatti N; Piacentini L; Niero F; Zanone Poma B; Galli M; Moroni M; Clerici M; Riva A
Am J Gastroenterol; 2006 Feb; 101(2):399-402. PubMed ID: 16454849
[TBL] [Abstract][Full Text] [Related]
17. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of interferon gamma for chronic hepatitis C.
Soza A; Heller T; Ghany M; Lutchman G; Jake Liang T; Germain J; Hsu HH; Park Y; Hoofnagle JH
J Hepatol; 2005 Jul; 43(1):67-71. PubMed ID: 15913831
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis.
Rocha CM; Perez RM; Ferreira AP; Carvalho-Filho RJ; Pace FH; Silva IS; Pestana JO; Lanzoni VP; Silva AE; Ferraz ML
Liver Int; 2006 Apr; 26(3):305-10. PubMed ID: 16584392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
